The Orphan Drug Act
- 1 April 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in American Journal of Clinical Oncology
- Vol. 39 (2), 210-213
- https://doi.org/10.1097/coc.0000000000000251
Abstract
The Orphan Drug Act has fostered drug development for patients with rare cancers and other diseases; however, current data suggest that companies are gaming the system to use the law for mainstream drugs. We identify a pattern of pharmaceutical companies submitting drugs to the Food and Drug Administration (FDA) as orphan drugs but once approved, the drugs are used broadly off-label with the lucrative orphan drug protections and exclusivity benefits. Since the law was passed, the proportion of new FDA-approved drugs that were submitted as orphan drugs has increased with a peak last year of 41% of all FDA-approved drugs approved as orphan drugs. On the basis of the current data, we suggest that patients with rare cancers and other diseases may suffer due to dilution of the incentives and benefits. We propose reform to increase submission scrutiny, decrease benefits based on off-label use, and increase price transparency.Keywords
This publication has 5 references indexed in Scilit:
- New approach to cancer therapy based on a molecularly defined cancer classificationCA: A Cancer Journal for Clinicians, 2013
- Unintended effects of orphan product designation for rare neurological diseasesAnnals of Neurology, 2012
- The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan DrugsPLOS ONE, 2012
- THE NEW DRUG APPROVALS OF 1993, 1994, AND 1995Clinical Journal of Sport Medicine, 1997
- Trends in Drug Development: The 1985-86 New Drug ApprovalsThe Journal of Clinical Pharmacology, 1987